PRECISION OPTICS CORPORATION, INC. 10-K

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA. Index to Financial Statements Page Report of Independent Registered Public Accounting Firm (PCAOB No. 577 ) F-1 Consolidated Balance Sheets at June 30, 2024 and 2023 F-3 Consolidated Statements of Operations for the Years Ended June 30, 2024 and 2023 F-4 Consolidated Statements of Stockholders’ Equity for the Years Ended June 30, 2024 and 2023 F-5 Consolidated Statements of Cash Flows for the Years Ended June 30, 2024 and 2023 F-6 Notes to Consolidated Financial Statements F-7 22 Report of Independent Registered Public Accounting Firm To the Board of Directors and Stockholders of Precision Optics Corporation, Inc. Opinion on the Consolidated Financial Statements We have audited the accompanying consolidated balance sheets of Precision Optics Corporation, Inc. (the “Company”) as of June 30, 2024 and 2023, and the related consolidated statements of income, comprehensive income, stockholders’ equity, and cash flows for each of the years in the two year period ended June 30, 2024, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of June 30, 2024 and 2023, and the results of its operations and its cash flows for each of the years in the two year period ended June 30, 2024, in conformity with accounting principles generally accepted in the United States of America. Basis for Opinion These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s consolidated financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion. Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion. Critical Audit Matters The critical audit matters communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate. F- 1 Revenue Recognition — Refer to Note A to the Consolidated Financial Statements Critical Audit Matter Description The Company recognizes revenue upon transfer of control of promised products to customers in an amount that reflects the consideration the Company expects to receive in exchange for those products. The Company may enter into certain customer contracts that contain unique, customer-specific terms and conditions, variable consideration, as well as multiple performance obligations. For such contracts, significant interpretation may be required to determine the appropriate accounting, including the identification of performance obligations, the allocation of the transaction price to performance obligations in the arrangement, the timing of the transfer of control of promised goods for each of those performance obligations, estimates of variable consideration and agent versus principal consideration. Our assessment of managements’ evaluation of the above referenced matters related to proper revenue recognition is significant to our audit because of the nature and extent of audit effort required to address the matter, the amounts are material to the financial statements, the assessment process involves significant auditor judgment, and the application of U.S. generally accepted accounting principles in this area is complex. How the Critical Audit Matter Was Addressed in the Audit Our principal audit procedures related to the Company’s revenue recognition for customer contracts included the following: · We evaluated the appropriateness of management’s revenue recognition policies. · We tested the mathematical accuracy of management’s calculations of revenue and the associated timing of revenue recognized in the consolidated financial statements. · We selected a sample of revenue transactions and performed the following procedures: o Obtained and read source documents for each selection, including master agreements, purchase orders and other documents that evidenced the customer arrangement. o Tested management’s identification and treatment of the key contract terms, including performance obligations and variable consideration. o Assessed the terms in the customer agreement and evaluated the appropriateness of management’s application of the Company’s accounting policies, along with their use of estimates, in the determination of revenue recognition conclusions. /s/ Stowe & Degon LLC Westborough, Massachusetts September 30, 2024 We have served as the Company’s auditor since 2008 F- 2 PRECISION OPTICS CORPORATION, INC. Consolidated Balance Sheets at June 30, 2024 and 2023 2024 2023 ASSETS Current Assets: Cash and cash equivalents $ 405,278 $ 2,925,852 Accounts receivable, net of allowance for credit losses of $ 118,872 at June 30, 2024 and $ 606,715 at June 30, 2023 3,545,491 3,907,407 Inventories 2,868,100 2,776,216 Prepaid expenses 299,364 249,681 Total current assets 7,118,233 9,859,156 Fixed Assets: Machinery and equipment 3,341,194 3,227,481 Leasehold improvements 810,914 825,752 Furniture and fixtures 416,425 242,865 Total fixed assets 4,568,533 4,296,098 Less—Accumulated depreciation and amortization 4,074,960 3,862,578 Net fixed assets 493,573 433,520 Operating lease right-of-use asset 189,999 358,437 Patents, net 286,559 265,111 Goodwill 8,824,210 8,824,210 Total other assets 9,300,768 9,447,758 TOTAL ASSETS $ 16,912,574 $ 19,740,434 LIABILITIES AND STOCKHOLDERS’ EQUITY Current Liabilities: Revolving line of credit $ 1,000,000 $ – Current portion of capital lease obligation 41,113 43,209 Current maturities of long-term debt 276,928 513,259 Accounts payable 1,397,313 2,432,264 Customer advances 1,172,350 1,174,690 Accrued compensation and other 840,662 927,521 Operating lease liability 178,450 168,677 Total current liabilities 4,906,816 5,259,620 Capital lease obligation, net of current portion 27,369 68,482 Long-term debt, net of current maturities 1,899,052 2,175,980 Operating lease liability, net of current portion 11,549 189,760 Total liabilities 6,844,786 7,693,842 Stockholders’ Equity: Common stock, $ 0.01 par value: 50,000,000 shares authorized; issued and outstanding – 6,073,939 shares at June 30, 2024 and 6,066,518 shares at June 30, 2023 60,739 60,665 Additional paid-in capital 61,197,433 60,224,934 Accumulated deficit ( 51,190,384 ) ( 48,239,007 ) Total stockholders’ equity 10,067,788 12,046,592 TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY $ 16,912,574 $ 19,740,434 The accompanying notes are an integral part of these consolidated financial statements. F- 3 PRECISION OPTICS CORPORATION, INC. Consolidated Statements of Operations for the Years Ended June 30, 2024 and 2023 2024 2023 Revenues $ 19,104,350 $ 21,044,467 Cost of goods sold 13,306,573 13,310,331 Gross profit 5,797,777 7,734,136 Research and development expenses, net 981,781 992,375 Selling, general and administrative expenses 7,540,329 7,380,309 Total operating expenses 8,522,110 8,372,684 Operating loss ( 2,724,333 ) ( 638,548 ) Other income (expense) Interest expense ( 225,108 ) ( 218,927 ) Gain on revaluation of contingent earn-out liability – 714,798 Loss before provision for income taxes ( 2,949,441 ) ( 142,677 ) Provision for income taxes 1,936 1,936 Net loss $ ( 2,951,377 ) $ ( 144,613 ) Loss per share: Basic and fully diluted $ ( 0.49 ) $ ( 0.03 ) Weighted average common shares outstanding: Basic and fully diluted 6,068,329 5,666,034 The accompanying notes are an integral part of these consolidated financial statements. F- 4 PRECISION OPTICS CORPORATION, INC. Consolidated Statements of Stockholders’ Equity for the Years Ended June 30, 2024 and 2023 Number of Shares Common Stock Additional Paid-in Capital Accumulated Deficit Total Stockholders’ Equity Balance, June 30, 2022 5,638,302 $ 56,383 $ 57,009,506 $ ( 48,094,394 ) $ 8,971,495 Issuance of common stock in private placement 420,000 4,200 2,284,082 – 2,288,282 Proceeds from exercise of stock option 8,216 82 12,314 – 12,396 Stock-based compensation – – 919,032 – 919,032 Net loss – – – ( 144,613 ) ( 144,613 ) Balance, June 30, 2023 6,066,518 $ 60,665 $ 60,224,934 $ ( 48,239,007 ) $ 12,046,592 Proceeds from exercise of stock option 4,333 43 12,746 – 12,789 Exercise of stock options net of 2,916 shares withheld 3,088 31 ( 31 ) – – Stock-based compensation – – 959,784 – 959,784 Net loss – – – ( 2,951,377 ) ( 2,951,377 ) Balance, June 30, 2024 6,073,939 $ 60,739 $ 61,197,433 $ ( 51,190,384 ) $ 10,067,788 The accompanying notes are an integral part of these consolidated financial statements. F- 5 PRECISION OPTICS CORPORATION, INC. Consolidated Statements of Cash Flows For the Years Ended June 30, 2024 and 2023 2024 2023 Cash Flows from Operating Activities: Net loss $ ( 2,951,377 ) $ ( 144,613 ) Adjustments to reconcile net loss to net cash (used in) provided by operating activities- Gain on revaluation of contingent earn-out liability – ( 705,892 ) Depreciation and amortization 212,382 210,735 Stock-based compensation expense 959,784 919,032 Non-cash interest expense 17,504 4,087 Changes in operating assets and liabilities: Accounts receivable, net 361,916 ( 1,243,535 ) Inventories ( 91,884 ) 245,931 Prepaid expenses ( 49,683 ) ( 36,233 ) Accounts payable ( 1,034,951 ) 193,089 Customer advances ( 2,340 ) 269,577 Accrued compensation and other ( 104,363 ) 206,732 Net cash used in operating activities ( 2,683,012 ) ( 81,090 ) Cash Flows from Investing Activities: Additional patent costs ( 21,448 ) ( 35,713 ) Purchases of property and equipment ( 272,435 ) ( 16,784 ) Net cash used in investing activities ( 293,883 ) ( 52,497 ) Cash Flows from Financing Activities: Payment of capital lease obligations ( 43,209 ) ( 40,705 ) Payments of long-term debt ( 513,259 ) ( 367,341 ) Issuance of long-term debt – 750,000 Payment of debt issuance costs – ( 22,275 ) Payment of acquisition earn-out liability – ( 166,667 ) Borrowings on revolving line of credit 1,000,000 – Gross proceeds from private placements of common stock – 2,288,281 Gross proceeds from exercise of stock options 12,789 12,397 Net cash provided by financing activities 456,321 2,453,690 Net increase (decrease) in cash and cash equivalents ( 2,520,574 ) 2,320,103 Cash and cash equivalents, beginning of year 2,925,852 605,749 Cash and cash equivalents, end of year $ 405,278 $ 2,925,852 Supplemental disclosure of cash flow information: Cash paid during the year for income taxes $ 1,936 $ 1,936 The accompanying notes are an integral part of these consolidated financial statements. F- 6 PRECISION OPTICS CORPORATION, INC. Notes to Consolidated Financial Statements (1) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (a) Nature of Business Precision Optics Corporation, Inc. (the “Company”) designs, develops, manufactures and sells specialized optical and illumination systems and related components. The Company conducts business in one industry segment only and its customers are primarily domestic. The Company performs advanced optical and illumination system design, development, assembly and manufacturing services, and sources for resale specialized optical components for products that fall into two principal areas: (i) medical products for use by hospitals and physicians; and (ii) products used by defense contractors and industrial customers. (b) Reverse Stock Split In February 2022, the Company’s Board of Directors authorized a reverse split of the Company’s outstanding shares of common stock within a stated range of 1:1.5 to 1:3, which was subsequently approved by stockholders holding more than a majority of the outstanding shares of Common Stock at the Company’s Annual Meeting on April 8, 2022. The Company effected the reverse stock split on a one-for-three basis on November 1, 2022, as reported by the Company on Form 8-K filed with the Securities and Exchange Commission on November 2, 2022. As a result of the reverse stock split, every three shares of issued and outstanding common stock were automatically combined into one issued and outstanding share of common stock, without any change in the par value per share or the number of the Company’s authorized shares. The reverse stock split reduced the number of shares of common stock outstanding from 16,915,089 on November 1, 2022, to approximately 5,638,302 shares, after reduction for the elimination of fractional shares. Unless otherwise noted, all prior year share amounts and per share calculations throughout these financial statements have been restated to reflect the impact of this 1:3 reverse stock split and to provide data on a comparable basis. Such restatements include calculations regarding the Company’s weighted-average shares, and earnings per share, as well as disclosures regarding the Company’s stock-based compensation plans. (c) Revenues The Company determines revenue recognition for arrangements that we determine are within the scope of Accounting Standards Codification Topic 606, Revenue from Contracts with Customers , (“ASC 606”), by performing the following five steps: (i) identify the contract with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when, or as, we satisfy the performance obligations. At contract inception, once the contract is determined to be within the scope of ASC 606, we assess the goods or services promised within the contract and determine those that are performance obligations and assess whether each promised good or service is distinct based on the contract. F- 7 The Company disaggregates revenues by product and service types as it believes best depicts how the nature, amount, timing and uncertainty of revenues and cash flows are affected by economic factors. Revenues are comprised of the following for year ended June 30, 2024, and 2023: Schedule of disaggregation of revenues Year Ended June 30, 2024 2023 Engineering Design Services $ 8,323,433 $ 6,728,867 Optical Components 8,384,140 10,523,806 Medical Device Products and Assemblies 2,396,777 3,791,794 Total Revenues $ 19,104,350 $ 21,044,467 Other selling costs to obtain and fulfill contracts are expensed as incurred due to the short-term nature of a majority of contracts. The Company extends terms of payment to its customers based on commercially reasonable terms for the markets of its customers, while also considering their credit quality. Shipping and handling costs charged to customers are included in revenue. Revenue recognition policies for each of the three product and service types appear below. Engineering Design Services The Company enters into contractual agreements with our customers, including design services agreements, statements of work and receive purchase orders for development projects. These agreements provide costs on an estimated basis for the services we have agreed to provide. Engineering Design Services are rendered on a time and materials basis. The Company recognizes revenue as customers are invoiced for the actual engineering services provided in the period. Revenue is also recognized on materials purchased for development projects at the time of receipt. Engineering Design Services are provided on a best-efforts basis; no warranty is provided as there is no guarantee that the work will result in the attainment of the customer’s project objectives. The Company may obtain customer deposits in advance of rendering engineering design services. Customer deposits are treated as contractual liabilities until the terms of customer agreements are satisfied and are not a component of revenue. Optical Components, Finished Products and Assemblies The Company provides fixed price quotations to our customers and requires purchase orders for all purchased optical components, finished devices and assemblies. Revenue is recognized at the time title passes to our customer based on our review of the customer contract, generally at the time of shipment from our facilities. Occasionally the Company may enter into “bill and hold” contractual arrangements where title is held by our customers while goods are stored at our facilities for their convenience. Technology Rights and Royalties The Company may recognize revenue for the sale of technology rights and through the receipt of royalties obtained under a license of our intellectual property. These revenues are recognized in the period in which, in our judgment, they are earned and no longer contingent under the terms and conditions of the relevant customer contract. F- 8 Contract Assets and Liabilities The nature of the Company’s products and services does not generally give rise to contract assets as it typically does not incur costs to fulfill a contract before a product or service is provided to a customer. The Company’s costs to obtain contracts are typically in the form of sales commissions paid to employees. The Company has elected to expense sales commissions associated with obtaining a contract as incurred as the amortization period is generally less than one year. These costs have been recorded in selling, general and administrative expenses. As of June 30, 2024 and 2023, there were no contract assets recorded in the Company’s Consolidated Balance Sheets. The Company’s contract liabilities arise as a result of unearned revenue received from customers at inception of contracts or where the timing of billing for services precedes satisfaction of performance obligations. The Company generally satisfies performance obligations within one year from the contract inception date. Contract liabilities, which were recorded as customer advances in the Company’s Consolidated Balance Sheets, and unearned revenue are comprised of the following: Schedule of contract liabilities Year Ended June 30, 2024 2023 Contract liabilities, beginning of period $ 1,174,690 $ 905,113 Unearned revenue received from customers 1,946,946 2,545,317 Revenue recognized ( 1,949,286 ) ( 2,275,740 ) Contract liabilities, end of period $ 1,172,350 $ 1,174,690 (d) Cash and Cash Equivalents The Company includes in cash equivalents all highly liquid investments with original maturities of three months or less at the time of acquisition. Cash and cash equivalents of $ 405,278 and $ 2,925,852 on June 30, 2024 and 2023, respectively, consist primarily of cash at banks and money market funds. The Company maintains its cash and cash equivalents in bank deposit accounts that, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts. The Company believes it is not exposed to any significant credit risk on its cash and cash equivalents. (e) Inventories Inventories are stated at the lower of cost (first-in, first-out) and net realizable value and include material, labor and manufacturing overhead. The components of inventories on June 30, 2024 and 2023 are as follows: Schedule of inventory 2024 2023 Raw material $ 1,570,135 $ 1,142,816 Work-in-progress 157,406 322,538 Finished goods 1,140,559 1,310,862 Total Inventories $ 2,868,100 $ 2,776,216 The Company provides for estimated obsolescence on unmarketable inventory based upon assumptions about future demand and market conditions. If actual demand and market conditions are less favorable than those projected by management, additional inventory write-downs may be required. Inventory, once written down, is not subsequently written back up, as these adjustments are considered permanent adjustments to the carrying value of the inventory. F- 9 (f) Fixed Assets Fixed assets are recorded at cost. Maintenance and repair items are expensed as incurred. The Company provides for depreciation and amortization by charges to operations, using the straight-line and declining-balance methods, which allocate the cost of fixed assets over the following estimated useful lives: Schedule of estimated useful lives Asset Classification Estimated Useful Life Machinery and equipment 2-7 years Leasehold improvements Shorter of lease term or estimated useful life Furniture and fixtures 5 years Vehicles 3 years Depreciation and amortization expense was $ 212,382 and $ 210,735 for the years ended June 30, 2024 and 2023, respectively. (g) Significant Customers and Concentration of Credit Risk Financial instruments that subject the Company to credit risk consist primarily of cash equivalents and trade accounts receivable. The Company places its investments with highly rated financial institutions. The Company has not experienced any losses on these investments to date. At June 30, 2024, and 2023, two individual customers accounted for more than 10 % of the Company’s total accounts receivable. The allowance for credit losses was $ 118,872 at June 30, 2024, and $ 606,715 at June 30, 2023. Schedule of allowance for credit losses Year Ended June 30, 2024 2023 Allowance for credit losses, beginning of period $ 606,715 $ 44,135 Change in the provision for expected credit losses ( 23,541 ) 567,066 Writeoffs charged against the allowance ( 464,302 ) ( 4,847 ) Allowance for credit losses, end of period $ 118,872 $ 606,715 In the year ended June 30, 2023, the Company increased the credit loss reserve to cover potential losses due to the insolvency of one customer and wrote off the receivable against the reserve during the year ended June 30, 2024. The Company generally does not require collateral or other security as a condition of sale, rather it relies on credit approval, balance limitation and monitoring procedures to control credit risk in trade account financial instruments. Management believes the allowance for credit losses, which is established based upon review of specific account balances and historical experience, is adequate at June 30, 2024. (h) Loss per Share Basic income (loss) per share is computed by dividing net income or net loss by the weighted average number of shares of common stock outstanding during the period. Diluted income (loss) per share is computed by dividing net income or net loss by the weighted average number of shares of common stock outstanding during the period, plus the number of potentially dilutive securities outstanding during the period such as stock options and warrants. For the years ended June 30, 2024 and 2023, the effect of such securities was antidilutive and not included in the diluted calculation because of the net loss generated in those periods. F- 10 The following is the calculation of loss per share for the years ended June 30, 2024 and 2023: Schedule of loss per share Year Ended June 30, 2024 2023 Net Loss– Basic and Diluted $ ( 2,951,377 ) $ ( 144,613 ) Basic and diluted weighted average shares outstanding 6,068,329 5,666,034 Loss per share Basic and fully diluted $ ( 0.49 ) $ ( 0.03 ) The number of shares issuable upon the exercise of outstanding stock options and warrants that were excluded from the computation as their effect was antidilutive was approximately 1,357,735 and 1,017,041 for the years ended June 30, 2024 and 2023, respectively. (i) Stock-Based Compensation The measurement and recognition of compensation costs for all stock-based awards made to employees and the Board of Directors are based upon fair value over the requisite service period for awards expected to vest. The Company estimates the fair value of share-based awards on the date of grant using the Black-Scholes option-pricing model. Stock-based compensation costs recognized for the years ended June 30, 2024, and 2023 amounted to $ 959,784 and $ 919,032 , respectively. (j) Goodwill and Patents Long-lived assets such as goodwill and patents are capitalized when acquired and reviewed for impairment whenever events or changes in circumstances indicate that the book value of the asset may not be recoverable. Impairment of the carrying value of long-lived assets such as goodwill and patents would be indicated if the best estimate of future undiscounted cash flows expected to be generated by the asset grouping is less than its carrying value. If an impairment is indicated, any loss is measured as the difference between estimated fair value and carrying value and is recognized in operating income or loss. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell. No such impairments of goodwill or patents have been estimated by management during the years ended June 30, 2024 or 2023. (k) Fair Value of Financial Instruments Financial instruments consist principally of cash and cash equivalents, accounts receivable and accounts payable. The estimated fair value of these financial instruments approximates their carrying value due to their short-term nature. (l) Research and Development Research and development expenses are charged to operations as incurred. The Company groups development and prototype costs and related reimbursements in research and development. There were no reimbursements for research and development recorded in research and development for the years ended June 30, 2024, and 2023. F- 11 (m) Comprehensive Income Comprehensive income or loss is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. The Company’s comprehensive loss or income for the years ended June 30, 2024 and 2023 was equal to its net loss for the same periods. (n) Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. In assessing the likelihood of utilization of existing deferred tax assets, management has considered historical results of operations and the current operating environment. (o) Segment Reporting Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions about how to allocate resources and assess performance. The Company’s chief decision-maker is its Chief Executive Officer. To date, the Company has viewed its operations and manages its business as principally one segment. (p) Use of Estimates The preparation of financial statements in conformity with accounting standards generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. (q) Recent Accounting Pronouncements In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which replaces the existing incurred loss impairment model with an expected credit loss model and requires a financial asset measured at amortized cost to be presented at the net amount expected to be collected. Public business entities classified as smaller reporting companies were required to apply the provision of ASU 2016-13 with annual reporting periods after December 15, 2022. The Company adopted the standard as of July 1, 2023, and the adoption of this guidance did not have a material impact on its consolidated financial statements and related disclosures. (2) BUSINESS ACQUISITION On October 4, 2021, the Company entered into an asset purchase agreement to acquire substantially all of the assets of Lighthouse Imaging, LLC, a medical optics and digital imaging business. The aggregate cash purchase price consisted of $ 2,855,063 in cash at closing, 833,333 shares of common stock and $ 1,500,000 as earn-out consideration over the subsequent two-year period. The earn-out consideration of $1,500,000, which would have been paid at a rate of $750,000 per annum from October 1, 2021 to September 30, 2023 was not paid because the required levels of gross profit were not attained. Accordingly, the Company recognized a gain on the revaluation of the contingent earn-out liability for the final year of the earn-out in the year ended June 30, 2023. F- 12 (3) COMMITMENTS (a) Bank Financing Activities Bank Line of Credit On October 4, 2021, the Company entered into a Loan Agreement with Main Street Bank of Marlborough, Massachusetts (“Lender”), which provided for a $2,600,000 Term Loan and a $250,000 Revolving Line of Credit Loan Facility, which was increased to $500,000 effective May 17, 2022, and $1,250,000 effective June 2, 2023. The $1,250,000 line of credit is due on demand and had $ 1,000,000 in borrowings outstanding at June 30, 2024. Borrowings under the line of credit bear interest payable monthly at the prime lending rate plus 1.5 % per annum and shall not be less than 4.75% per annum. Borrowings under the line of credit are limited to the borrowing base comprised of a percentage of accounts receivable and inventory and are secured by all the assets of the Company. The Company’s Loan Agreement with the Lender contains a minimum annual debt service coverage ratio covenant of 1.2x, for the period ending June 30, 2024. The Company did not meet this annual debt service coverage ratio as of such fiscal year end date. The Company’s Lender has agreed to waive compliance with such debt service ratio covenant for the period ending June 30, 2024. In connection with its waiver the Company will pay a waiver fee of $ 5,000 . In addition to such waiver, the Lender and the Company have entered into an amendment dated September 30, 2024 to that certain Term Loan dated October 4, 2021, as amended and that certain Promissory Note dated June 2, 2023 (collectively, the “Notes”) which amendments provide for a six month period of interest only payments from September 15, 2024 through February 15, 2025 for the Notes. The Company will begin to pay principal and interest under the Notes beginning with the payments due on March 15, 2025, with a new amortization schedule for the remaining term for such Notes through their maturity date. There were no other changes to or modifications to the Loan Agreement or the Notes. Long-Term Debt Long-term debt consists of the following at June 30, 2024: Schedule of long-term debt Amount Term Loan Note payable to Main Street Bank with monthly principal payments of $ 30,952 , excluding six months in Fiscal 2025, plus interest at the prime lending rate plus 1.5 % per annum. Secured by all assets of the Company, and subject to certain periodic reporting to the bank, an annual minimum debt service coverage ratio of 1.20:1 commencing with the fiscal year ending June 30, 2023, and other conditions. The Term Loan Note matures on October 15, 2028 $ 1,609,524 Permanent Working Capital Loan payable to Main Street Bank with monthly principal payments of $ 12,500 excluding six months in Fiscal 2025, plus interest at a fixed rate of 8.625 % per annum. Secured by all assets of the Company, and subject to certain periodic reporting to the bank, an annual minimum debt service coverage ratio of 1.20:1 commencing with the fiscal year ending June 30, 2023, and other conditions. The Term Loan Note matures on June 15, 2028 600,000 Less current maturities ( 276,928 ) Less debt issuance costs, net of accumulated amortization of $ 14,360 . ( 33,544 ) Long-term debt, net of current portion of debt issuance costs $ 1,899,052 F- 13 At June 30, 2024 principal payments due on long-term debt are as follows: Schedule of principal payments due on loan term debt Fiscal Year Ending June 30: 2025 $ 285,097 2026 594,578 2027 594,578 2028 594,578 2029 140,693 Total long-term debt $ 2,209,524 (b) Lease Obligation In March 2021 the Company entered into a five-year capital lease in the amount of $ 161,977 and in January 2020, the Company entered into a five-year capital lease for $ 47,750 , both for manufacturing equipment. The net book value of fixed assets under capital lease obligations as of June 30, 2024 is $ 71,107 . On July 1, 2019 the Company entered into a three-year operating lease for its facility in El Paso, Texas, and in February 2022 the Company entered into an extension of the lease for an additional three years through June 2025. Remaining minimum lease payments at June 30, 2024 total $ 46,047 . Total lease costs including base rent and common area expenses was $ 64,621 and $ 67,534 during the fiscal years ended June 30, 2024 and 2023, respectively. On October 4, 2021 the Company assumed the remaining term of the Windham Maine lease as part of the Lighthouse acquisition. The lease expires on July 31, 2025. Remaining minimum lease payments at June 30, 2024 total $ 144,943 . Total lease costs including base rent and common area expenses was $ 137,728 and $ 141,351 during the fiscal year ended June 30, 2024 and 2023, respectively. The amount of variable lease payments is immaterial. Included in the accompanying balance sheet at June 30, 2024 is a right-of-use asset of $ 189,999 and current and long-term right-of-use operating lease liabilities of $ 178,450 and $ 11,549 , respectively. At June 30, 2024 future minimum lease payments under the capital lease and operating lease obligations are as follows: Schedule of future minimum lease payments under the capital lease and operating lease obligations Fiscal Year Ending June 30: Capital Leases Operating Lease 2025 $ 43,919 $ 183,319 2026 28,028 11,933 Total Minimum Payments 71,947 195,252 Less: amount representing interest 3,465 5,253 Present value of minimum lease payments 68,482 189,999 Less: current portion 41,113 178,450 Future minimum long-term lease liability $ 27,369 $ 11,549 The Company’s four facilities in Gardner, Massachusetts which are used for offices, production and storage spaces are leased primarily on a tenant-at-will basis. Rent expense on these operating leases was $ 200,678 and $ 191,088 for the fiscal years ended June 30, 2024 and 2023, respectively. F- 14 (4) STOCKHOLDERS’ EQUITY (a) Stock-Based Compensation Expense The following table summarizes stock-based compensation expense for the years ended June 30: Schedule of stock-based compensation expense 2024 2023 Cost of Goods Sold $ 93,713 $ 34,966 Research and Development Expenses – 182,498 Selling, General and Administrative Expenses 866,071 701,568 Stock Based Compensation Expense $ 959,784 $ 919,032 As of June 30, 2024, the unrecognized compensation costs related to options vesting in the future is $ 1,053,617 . No compensation has been capitalized because such amounts would have been immaterial. There was no net income tax benefit recognized related to such compensation for the years ended June 30, 2024, or 2023, as the Company is currently in a loss position. There were 285,527 stock options granted during the year ended June 30, 2024, and 267,336 stock options granted during the year ended June 30, 2023. The Company uses the Black-Scholes option-pricing model as the most appropriate method for determining the estimated fair value for the stock awards. The Black-Scholes method of valuation requires several assumptions: (1) the expected term of the stock award; (2) the expected future stock volatility over the expected term; and (3) risk-free interest rate. The expected term represents the expected period of time the Company believes the options will be outstanding based on historical information. Estimates of expected future stock price volatility are based on the historic volatility of the Company’s common stock and the risk-free interest rate is based on the U.S. Zero-Bond rate. The Company utilizes a forfeiture rate based on an analysis of the Company’s actual experience. The fair value of options at date of grant was estimated with the following assumptions for options granted in fiscal year 2024: Schedule of fair value of option assumptions Year Ended June 30, 2024 June 30, 2023 Assumptions: Option life 6.25 years 5.3 years Risk-free interest rate 4.35 - 4.47 % 3.0 - 7.0 % Weighted average stock volatility 99.4 % 101.9 % Dividend yield 0.0 % 0.0 % Weighted average fair value of grants $ 4.69 $ 4.77 (b) Stock Option Plans The type of share-based payments currently utilized by the Company is stock options. The Company has four stock option plans outstanding as of June 30, 2024, namely the Precision Optics Corporation, Inc. 2022 Equity Incentive Plan (the “2022 Plan”), the Precision Optics Corporation, Inc. 2021 Equity Incentive Plan (the “2021 Plan”), the Precision Optics Corporation, Inc. 2011 Equity Incentive Plan (the “2011 Plan”) and the Precision Optics Corporation, Inc. 2006 Equity Incentive Plan (the “2006 Plan”). Vesting periods under each of the Plans are at the discretion of the Board of Directors and typically average three years and in some instances are subject to future performance criteria. Options under these Plans are granted at fair market value on the date of grant and typically have an initial term of ten years from the date of grant, subject to certain cancellation provisions such as upon employment termination. The Company has filed Registration Statements on Form S-8 with the Securities and Exchange Commission to register all shares of common stock issuable under the 2022, 2021, 2011, and 2006 Plans. F- 15 On April 8, 2022, our Shareholders approved the 2022 Plan which provides eligible participants (certain employees, directors, consultants, etc.) the opportunity to receive a broad variety of equity based and cash awards. A maximum of 633,333 shares of the Company’s common stock may be issued pursuant to stock options or other awards under the 2022 Plan. At June 30, 2024, options for a total of 485,258 shares of common stock were outstanding and 148,075 shares of common stock were available for future grants under the 2022 Plan. The 2022 Plan permits the Board of Directors to authorize and increase of up to 5% of the then outstanding shares on an annual basis. On May 10, 2021, our Board of Directors approved the 2021 Plan which likewise authorizes a broad variety of equity based and cash awards. A maximum of 333,333 shares of the Company’s common stock may be issued under the 2021 Plan. At June 30, 2024, options for a total of 247,326 shares of common stock were outstanding under the 2021 Plan and 80,786 shares of common stock were available for future grants under the 2021 Plan. The 2011 Plan and 2006 Plan likewise provided for a broad variety of equity based and cash awards, but terminated in 2021 and 2016, respectively. At June 30, 2024, options for 614,252 shares of common stock were outstanding under the 2011 Plan. At June 30, 2024, options for a total of 10,899 shares of common stock were outstanding under the 2006 Plan. The following tables summarize stock option activity for the years ended June 30, 2024 and 2023: Schedule of stock option activity Options Outstanding Number of Shares Weighted Average Exercise Price Weighted Average Contractual Life Outstanding at June 30, 2022 904,667 $ 3.99 7.08 years Grants 294,003 $ 6.27 Exercised ( 8,523 ) $ 3.05 Cancellations ( 63,007 ) $ 5.87 Outstanding at June 30, 2023 1,127,140 $ 4.54 6.88 years Grants 285,257 $ 5.76 Exercised ( 10,332 ) $ 2.70 Cancellations ( 44,330 ) $ 4.18 Outstanding at June 30, 2024 1,357,735 $ 4.72 6.60 years The aggregate intrinsic value of the Company’s “in-the-money” outstanding and exercisable options as of June 30, 2024, was $ 1,820,411 and $ 1,761,704 , respectively. (c) Sale of Stock in June 2023 On June 15, 2023, the Company entered into agreements with certain institutional and accredited investors for the sale and purchase of 420,000 unregistered shares of its common stock, $ 0.01 par value at a purchase price of $ 6.00 per share. The Company used the net proceeds from this placement for general working capital needs. In conjunction with the placement, the Company also entered into a registration rights agreement with the investors, whereby it registered the resale by the investors of 420,000 shares of its common stock purchased in the placement on a registration statement that was filed on July 20, 2023, and became effective on October 18, 2023. F- 16 (d) Sale of Stock in August 2024 On August 14, 2024, the Company entered into agreements with certain institutional and accredited investors, in addition to certain directors and officers of the Company, for the sale and purchase of 265,868 shares of the Company’s common stock as further described in Footnote 7, Subsequent Events. (5) INCOME TAXES The Company has identified its federal tax return and its state tax return in Massachusetts as “major” tax jurisdictions. The periods subject to examination for its federal and state income tax returns are the years ended in 2018 and thereafter. The Company believes its income tax filing positions and deductions will be sustained on audit and it does not anticipate any adjustments that would result in a material change to its financial position. Therefore, no liabilities for uncertain income tax positions have been recorded. The provision for income taxes in the accompanying consolidated statements of operations consists of the state income tax liability of $ 1,936 for the years ended June 30, 2024, and 2023. A reconciliation of the federal statutory rate to the Company’s effective tax rate for the fiscal years ended June 30, 2024 and 2023 is as follows: Schedule of effective income tax rate reconciliation 2024 2023 Income tax expense (benefit) at federal statutory rate ( 21.0 )% ( 21.0 )% Increase (decrease) in tax resulting from: State taxes, net of federal benefit ( 6.3 )% ( 5.8 )% Change in valuation allowance ( 16.3 )% ( 23.3 )% Stock based compensation 10.5 % 176.0 % Net Operating Loss Utilization – % 5.0 % Revaluation of contingent earn out liability – % ( 135.2 )% Nondeductible items 0.4 % 5.6 % Effective tax rate 0.0 % 1.3 % The components of deferred tax assets and liabilities at June 30, 2024 and 2023 are approximately as follows: Schedule of deferred tax assets and liabilities 2024 2023 Deferred tax assets: Net operating loss carry forwards $ 3,999,000 $ 2,617,000 Tax credit carry forwards 353,000 247,000 Reserves and accruals not yet deducted for tax purposes 254,000 407,000 Total deferred tax assets 4,606,000 3,271,000 Valuation allowance ( 4,606,000 ) ( 3,271,000 ) Net deferred tax asset $ – $ – The Company has provided a valuation allowance to reduce the net deferred tax asset to an amount the Company believes is “more likely than not” to be realized. At June 30, 2024, the Company had federal and state net operating loss carry forwards of approximately $ 16,418,000 and $ 8,717,000 , respectively, which will, if not used, expire at various dates beginning in fiscal year 2025. F- 17 (6) PROFIT SHARING PLAN The Company has a defined contribution 401(k) profit sharing plan. Employer profit sharing and matching contributions to the plan are discretionary. No employer profit sharing or matching contributions were made to the plan in fiscal years 2024 and 2023. (7) SUBSEQUENT EVENTS On August 14. 2024 the Company entered into securities purchase agreements with institutional and accredited investors in addition to certain directors and officers of the Company for the purchase and sale of 265,868 shares of the Company’s common stock pursuant to a registered direct offering at a purchase price of $5.25 per share for the institutional and unaffiliated accredited investors and $5.79 per share for the directors and officers, resulting in gross proceeds of approximately $1.4 million before deducting placement agent commissions and other estimated offering expenses. Net proceeds were approximately $1.2 million. F- 18 ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE. None.